Edetate Disodium Error (Endrate Error) - Hospital Malpractice / Phamacy Malpractice - Wrongful Death

EDETATE DISODIUM (ENDRATE) LAWSUIT - FDA HEALTH ADVISORY: Below is the FDA health advisory regarding potential death and serious injury when patients have been given Edetate Disodium (Endrate) instead of another medication with a similar name, Edetate Calcium Disodium.

Pritzker | Olsen, P.A., a nationally-recognized law firm, is reprinting the health advisory as a public service. The firm has a national practice in both the areas of defective medical product litigation and malpractice and is representing families in wrongful death cases in both areas. To contact the firm, please call toll-free at 1-888-377-8900 or submit the firm's online consultation form.

FDA Public Health Advisory
January 16, 2008 - Edetate Disodium (marketed as Endrate and generic products):

Syringe FDA is issuing this public health advisory to alert patients and healthcare professionals about important safety information concerning the drug Edetate Disodium. There have been cases where children and adults have died when they were mistakenly given Edetate Disodium instead of Edetate Calcium Disodium (Calcium Disodium Versenate) or when Edetate Disodium was used for "chelation therapies" and other uses that are not approved by the FDA. As a result, FDA is reviewing the benefit/risk profile of Edetate Disodium to determine if the benefits for its intended use continue to outweigh the serious risks. [Note: Hospira Inc., the manufacturer of Endrate, has stopped selling Endrate in response to this FDA health advisory and the deaths associated with Edetate Disodium.]

These two drugs have very similar names and are commonly referred to only as “EDTA.” As a result, the two products are easily mistaken for each other when prescribing, dispensing, and administering them. [When the wrong medication, such as Edetate Disodium, is prescribed, dispensed or administered, any resulting injury may be the basis of a malpractice claim against a hospital, doctor or pharmacy.]

Edetate Disodium and Edetate Calcium Disodium work by binding with heavy metals or minerals in the body allowing them to be passed out of the body through the urine.
The FDA originally approved the two drugs for very specific and very different purposes as described below.

Edetate Disodium was approved many years ago as an emergency treatment for certain patients with a condition called hypercalcemia (very high levels of calcium in the blood) or certain patients with heart rhythm problems as a result of very high amounts of digitalis in the blood. However, there are newer drugs that have been approved since that time that treat these conditions.
Edetate Calcium Disodium was also approved many years ago and is still used to reduce dangerously high blood lead levels (severe lead poisoning). This drug is medically necessary because there are very few other drugs available to treat severe lead poisoning.

Over time, a number of uses that are not FDA approved for these products have evolved in clinical settings. Among these uses are the removal of other heavy metals from the blood and the treatment of heart disease (coronary artery disease), commonly referred to “chelation therapies.”

On March 3, 2006, the Centers for Disease Control and Prevention published an article in the Morbidity and Mortality Weekly Report documenting the deaths of people given Edetate Disodium instead of Edetate Calcium Disodium (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm). FDA was informed early in 2007 of an additional child’s death as a result of a mix-up between the two drugs. Because of the potential for these medication errors to be fatal, the CDC recommended that hospitals evaluate their need to keep Edetate Disodium stocked in their pharmacies. FDA supports this recommendation as a means of reducing the risk of confusing the two drugs.

FDA is issuing this advisory to highlight the following important safety considerations until the ongoing evaluation of the risks and benefits of Edetate Disodium is complete.

Because of the potential for these medication errors to be fatal, the FDA and CDC recommend that hospitals evaluate their need to keep Edetate Disodium stocked in their pharmacies.
If your facility determines that there is no need to have a supply of Edetate Disodium, consider removing the product from stock to reduce the risk of confusion with Edetate Calcium Disodium.
The safety or effectiveness of Edetate Disodium or Edetate Calcium Disodium for use in removing heavy metals and toxins from the body, use in treating coronary artery disease, or other uses not described in the labeling for the product have not been established.
Children and adults who are to be treated for lead poisoning should only be given the Edetate Calcium Disodium (Calcium Disodium Versenate) form of "EDTA."
Use the full product name. Do not use the abbreviation “EDTA” when prescribing or dispensing an order for either of the drugs.
Consider including the indication for use of the product on the prescribing order.
Hospitals, pharmacies and healthcare providers should always check the prescribing order and the label of the drug to confirm that the correct drug has been selected for use before dispensing and administering the drug to a patient.

Free Case Consultation

We are Not Paid Unless You Win

Our attorneys work on a continguency fee basis, meaning you do not have to pay our law firm for representing you unless we win you money.

Firm News

AV Preeminent Rating by Martindale-Hubbell

Attorneys Fred Pritzker and Eric Hageman have been given the highest rating by Martindale-Hubbell for attorney, AV Preeminent. An AV® certification mark is a significant rating accomplishment - a testament to the fact that a lawyer's peers rank him or her at the highest level of professional excellence.

Adjunct Teaching Position At U of M Law School

Attorney Brendan Flaherty has accepted an adjunct teaching position at the University of Minnesota Law School. For the 2011 spring semester, Flaherty will teach a course entitled "Practice and Professionalism," which will introduce students to foundational lawyering skills and professional responsibility issues.

Attorney Elliot Olsen Speaks at Conference

Attorney Elliot Olsen recently spoke at the Seventh Annual LifeScience Alley Conference in Minneapolis on Preemption and the Future of Medical Device Litigation. He appeared with Randall Pattee of Lindquist and Vennum and Jean Lance, VP of corporate legal and general counsel for Boston Scientific.

Named Super Lawyer

In recognition of their achievements, Attorneys Fred Pritzker, Elliot Olsen and Eric Hageman were named "Super Lawyers" by Law & Politics magazine. According to Super Lawyers, "The objective is to create a credible, comprehensive and diverse listing of outstanding attorneys that can be used as a resource to assist attorneys and consumers in the search for legal counsel."

Brendan Flaherty Named a Rising Star

In recognition of his achievements, Attorney Brendan Flaherty was named a 2010 Rising Star by Minnesota Law & Politics. Only 2.5 percent of the state’s lawyers are included on the list, which highlights Minnesota’s best up-and-coming legal talent.

Fred Pritzker Listed in The Best Lawyers in America

Fred Pritzker has been notified that he will again be listed in The Best Lawyers in America for his work in personal injury litigation.

This is attorney advertising. Past results do not guarantee a similar outcome. The result of each case is determined by the specific facts and the applicable law.